Open AccessIs chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study
Author(s) -
Lu MingShian,
Chen MiaoFen,
Lin ChienChao,
Tseng YuanHsi,
Huang YaoKuang,
Liu HuiPing,
Tsai YingHuang
Publication year - 2017
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12414
Subject(s) - medicine , lung cancer , kidney disease , renal function , hazard ratio , propensity score matching , risk factor , comorbidity , retrospective cohort study , confidence interval , oncology
Background Comorbidity has a great impact on lung cancer survival. Renal function status may affect treatment decisions and drug toxicity. The survival outcome in lung cancer patients with coexisting chronic kidney disease ( CKD) has not been fully evaluated. We hypothesized that CKD is an independent risk factor for mortality in patients with lung cancer. Methods A retrospective, propensity‐matched study of 434 patients diagnosed between J une 2004 and M ay 2012 was conducted. CKD was defined as estimated glomerular filtration rate <60 mL/minute. Lung cancer and coexisting CKD patients were matched 1:1 to patients with lung cancer without CKD . Results Age, gender, smoking status, histology, and lung cancer stage were not statistically significantly different between the CKD and non‐ CKD groups. Kaplan– M eier survival analysis demonstrated a median survival of 7.26 months (95% confidence interval [ CI] 6.06–8.46) in the CKD group compared with 7.82 months (95% CI 6.33–9.30) in the non‐ CKD group ( P = 0.41). Lung cancer stage‐specific survival is not affected by CKD . Although lung cancer patients with CKD presented with an increased risk of death of 6%, this result was not statistically significant ( hazard ratio 1.06, 95% CI 0.93–1.22; P = 0.41). Conclusion According to our limited experience, CKD is not an independent risk factor for survival in lung cancer patients. Clinicians should not be discouraged to treat lung cancer patients with CKD .